Company profile

Apollo Therapeutics

Biologics developed via academic-collaboration model

Privately held: no public share price · UK

Assets

(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
APL-9796
Phase 2
ZIP12 (zinc transporter)Monoclonal antibody
Hypertension
camoteskimab
Phase 2
IL-18Monoclonal antibody
Atopic Dermatitis
APL-4098
Phase 1
GCN2 (EIF2AK4)
Acute Myeloid Leukemia

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.